Giovanni Caforio (Photographer: Christopher Goodney/Bloomberg via Getty Images)

Bris­tol My­ers Squibb out­races the pack to a late-stage tri­al win for its LAG-3/PD-1 an­ti­body com­bo in melanoma

As one of bio­phar­ma’s many shots on goal at new check­point in­hibitors, the LAG-3 class has, pun in­tend­ed, lagged be­hind with lit­tle mean­ing­ful da­ta to show. But a num­ber of big drug­mak­ers have rea­son to be­lieve that a LAG-3 and PD-1 com­bo could solve the puz­zle in on­col­o­gy — and new da­ta from Bris­tol My­ers Squibb help that case.

A com­bi­na­tion of an­ti­body re­latlimab and PD-1 in­hibitor Op­di­vo sig­nif­i­cant­ly ex­tend­ed pro­gres­sion-free sur­vival over Op­di­vo alone in first-line melanoma pa­tients whose tu­mors are ei­ther metasta­t­ic or un­able to be sur­gi­cal­ly re­moved, ac­cord­ing to topline da­ta from the Phase III REL­A­TIV­I­TY-047 study re­leased Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.